Clinical relevance of JAK2 (V617F) mutant allele burden

被引：60
|
作者：
Passamonti, Francesco [1 ]
Rumi, Elisa [1 ]
机构：
[1] Univ Pavia, Fdn IRCCS Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 01期
关键词：
POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; WILD-TYPE; MUTATION; JAK2V617F; MYELOFIBROSIS; JAK2(V617F); RISK; PROGRESSION; GRANULOCYTE;
D O I：
10.3324/haematol.2008.001271
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：7 / 10
页数：4
相关论文
共 50 条
  • [21] JAK2 V617F Mutation Status of 232 Patients Diagnosed With Chronic Myeloproliferative Neoplasms
    Payzin, Kadriye Bahriye
    Savasoglu, Kaan
    Alacacioglu, Inci
    Ozdemirkiran, Fusun
    Mutlu, Belgin Berber
    Bener, Sadi
    Calli, Aylin Orgen
    Kucukzeybek, Betul Bolat
    Aksun, Saliha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (06): : 525 - 533
  • [22] The JAK2 V617F mutation in patients with cerebral venous thrombosis
    Passamonti, S. M.
    Biguzzi, E.
    Cazzola, M.
    Franchi, F.
    Gianniello, F.
    Bucciarelli, P.
    Pietra, D.
    Mannucci, P. M.
    Martinelli, I.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (06) : 998 - 1003
  • [23] The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study
    Perricone, Margherita
    Polverelli, Nicola
    Martinelli, Giovanni
    Catani, Lucia
    Ottaviani, Emanuela
    Zuffa, Elisa
    Franchini, Eugenia
    Dizdari, Arbana
    Forte, Dorian
    Sabattini, Elena
    Cavo, Michele
    Vianelli, Nicola
    Palandri, Francesca
    ONCOTARGET, 2017, 8 (23) : 37239 - 37249
  • [24] Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F
    Bandaranayake, Rajintha M.
    Ungureanu, Daniela
    Shan, Yibing
    Shaw, David E.
    Silvennoinen, Olli
    Hubbard, Stevan R.
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2012, 19 (08) : 754 - 759
  • [25] Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients
    Besses, Carlos
    Alvarez-Larran, Alberto
    Martinez-Aviles, Luz
    Mojal, Sergi
    Longaron, Raquel
    Salar, Antonio
    Florensa, Lourdes
    Serrano, Sergi
    Bellosillo, Beatriz
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (04) : 413 - 419
  • [26] JAK2 V617F mutation in Iranian patients with myeloproliferative neoplasms: clinical and laboratory findings
    Poopak, Behzad
    Farshdousti Hagh, Majid
    Saki, Najmaldin
    Elahi, Fazel
    Rezvani, Hamid
    Khosravipour, Gelareh
    Jahangirpour, Mohammad Ali
    Bolouri, Shirin
    Golkar, Tolou
    Falah, Parviz
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2013, 43 (03) : 347 - 353
  • [27] JAK2 (V617F) mutation in healthy individuals
    Passamonti, Francesco
    Rumi, Elisa
    Pietra, Daniela
    Lazzarino, Mario
    Cazzola, Mario
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (04) : 678 - 679
  • [28] JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms
    Wang, J.
    Xu, Z.
    Liu, L.
    Gale, R. P.
    Cross, N. C. P.
    Jones, A. V.
    Qin, T.
    Ai, X.
    Xu, J.
    Zhang, T.
    Sun, X.
    Li, Q.
    Zhang, P.
    Zhang, Y.
    Xiao, Z.
    LEUKEMIA, 2013, 27 (08) : 1763 - 1767
  • [29] Rapid quantification of JAK2 V617F allele burden using a bead-based liquid assay with locked nucleic acid-modified oligonucleotide probes
    Shivarov, Velizar
    Ivanova, Milena
    Hadjiev, Evgueniy
    Naumova, Elissaveta
    LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 2023 - 2026
  • [30] Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms
    Horvat, Ivana
    Boban, Ana
    Zadro, Renata
    Antolic, Margareta Radic
    Serventi-Seiwerth, Ranka
    Roncevic, Pavle
    Radman, Ivo
    Sertic, Dubravka
    Vodanovic, Marijo
    Pulanic, Drazen
    Basic-Kinda, Sandra
    Durakovic, Nadira
    Zupancic-Salek, Silva
    Vrhovac, Radovan
    Aurer, Igor
    Nemet, Damir
    Labar, Boris
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (01): : 53 - 63
12345